Clinical trials
Metastatic Lung Cancer clinical trials
Below are recruiting metastatic lung cancer clinical trials, each written for real people, not researchers. We’re tracking 1,188 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05955170RecruitingPhase 2
Tucatinib plus oral chemo and trastuzumab for metastatic HER2+ breast cancer
This Phase 2 trial studies tucatinib combined with oral etoposide and trastuzumab in people with metastatic HER2-positive breast cancer, aiming to slow cancer growth. You may be eligible if you previously had progression on a similar HER2-targeted treatment or cannot take capecitabine for medical reasons.
Clermont-Ferrand, Clermont FerrandAges 18 years+ - NCT06832202RecruitingPhase 2
HLX22 plus Enhertu for HR+, HER2-low breast cancer
This trial tests a new drug, HLX22, combined with Enhertu (trastuzumab deruxtecan) for people with advanced breast cancer that is hormone receptor positive and HER2-low. The goal is to see if the combination works better than Enhertu alone.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05954429RecruitingPhase 2
Study of fruquintinib plus immunotherapy after standard CRC treatment
This trial studies fruquintinib combined with serplulimab (an immune therapy) for advanced colorectal cancer that has spread and is no longer responding to standard treatments. It may help by slowing the cancer’s growth and improving outcomes after the usual options have been tried.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04923542RecruitingPhase 1/Phase 2
Targeted drug plus focused brain radiation for breast cancer
This study tests whether abemaciclib (a targeted pill) given with focused radiation to brain tumors can control hormone receptor–positive, HER2-negative breast cancer in the brain. It’s designed to see if the combination helps shrink or slow the growth of brain metastases while keeping side effects manageable.
Tampa, FloridaAges 18 years+ - NCT04090567RecruitingPhase 2
Olaparib with two partners for advanced BRCA breast cancer
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
Houston, TexasAges 18 years+ - NCT07062263RecruitingPhase 3
Trastuzumab with chemo for HER2+ bile duct cancer
This trial tests if adding trastuzumab to standard chemotherapy can help people with advanced bile duct or gallbladder cancer that tests positive for HER2. The study aims to see if the combination works better than chemotherapy alone.
Muzaffarpur, BiharAges 18–99 - NCT07065435RecruitingPhase 2
RC48 with Avastin or Pyrotinib for HER2+ breast cancer after T-DXd
This trial tests a new combination of drugs (RC48 plus either Avastin or Pyrotinib) for people with HER2-positive breast cancer that has spread and has stopped responding to the drug T-DXd. The goal is to see if these combinations can help shrink tumors and control the cancer longer.
Nanjing, JiangsuAges 18–75 - NCT06689163RecruitingPhase 1/Phase 2
Study of HRS-1167 with abiraterone for metastatic prostate cancer
This trial tests a new combination of two study drugs (HRS-1167 and abiraterone with prednisone) for men with prostate cancer that has spread beyond the prostate. The goal is to see if the combination works better than current treatments.
Hefei, AnhuiAges 18 years+ - NCT07446452RecruitingPhase 2
Combination treatment for HER2-low advanced breast cancer
This trial tests a combination of two drugs, disitamab vedotin and bevacizumab, for people with a specific type of advanced breast cancer called HER2-low. It is designed for those who have already been treated with a drug called T-DXd and need further options.
Nanjing, JiangsuAges 18–75 - NCT06439888RecruitingPhase 1/Phase 2
Immune cells plus radiation for limited-stage cancer spread
This trial tests whether giving immune-supporting cells (lymphocytes) alongside focused radiation (SBRT) can help control limited cancer spread. People with 1 to 5 small tumors that can all be radiated within two weeks may be eligible.
LyonAges 18 years+ - NCT06962267RecruitingPhase 2
Study of TQB2916 with chemo for advanced pancreatic cancer
This trial tests a new drug (TQB2916) combined with standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for metastatic pancreatic cancer. It aims to see if the combination works better than chemo alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT07454642RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug called AVA6103 for people with certain advanced solid tumors that have not responded to standard treatments. The drug may help by targeting a protein on cancer cells and interfering with their ability to multiply.
Scottsdale, ArizonaAges 18 years+ - NCT05896839RecruitingPhase 1/Phase 2
Immunotherapy with prednisone and sirolimus for transplant skin cancer
This early-phase study tests whether adding immunotherapy (nivolumab and ipilimumab) to prednisone and sirolimus can control advanced skin cancers in people with kidney transplants. It aims to see how well the treatment works and how safe it is for transplant recipients.
La Jolla, CaliforniaAges 18 years+ - NCT06551207Recruiting
New drug combo with radiation for advanced MSS colon cancer
This trial tests a new combination—an immunotherapy drug (cadonilimab) plus a targeted anti-angiogenesis pill (fruquintinib) and focused radiation (SBRT)—for people with MSS colorectal cancer that has progressed after at least two prior treatments. The goal is to see if this triple approach can help shrink or control the cancer better than standard options.
Wuhan, HubeiAges 18–75 - NCT07638774Recruiting
Compression Gloves and Socks to Prevent Nerve Damage from UTD1 Cancer Drug
This study tests whether wearing special compression and cooling gloves and socks can help prevent nerve damage (numbness and tingling in hands and feet) that sometimes occurs in women receiving a breast cancer medication called UTD1. You would wear these gloves and socks during and after your chemotherapy treatment.
ShanghaiAges 18–75 - NCT07551440Recruiting
Finding treatment targets in advanced gastric cancer
This study looks for specific genetic or molecular markers in advanced gastric cancer that has spread to other parts of the body. The goal is to identify which treatments might work best for each patient's individual cancer.
Hong KongAges 18–80 - NCT07535112RecruitingPhase 1
Study of a new drug for advanced colorectal cancer with KRAS G12D mutation
This trial tests an experimental drug (BAY 3771249) for people with advanced or metastatic colorectal cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and if it can help shrink tumors.
Phoenix, ArizonaAges 18 years+ - NCT07519655RecruitingPhase 1
New Cancer Drug Treatment for Advanced Lung, Esophageal, or Skin Cancer
This study tests a new drug called PF-08046033 in people with advanced lung cancer (NSCLC), esophageal cancer (ESCC), or melanoma (skin cancer) that has spread or can't be surgically removed. The drug targets a specific protein to help slow or stop cancer growth.
Denver, ColoradoAges 18 years+ - NCT07394218RecruitingPhase 2
Tumor DNA Blood Test to Guide Breast Cancer Treatment
This trial tests whether using a blood test for tumor DNA can help doctors decide the best treatment for people with HER2-negative breast cancer that has spread. It focuses on a type of therapy called an antibody-drug conjugate (ADC) and aims to personalize your care.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07222800RecruitingPhase 3
Testing a new drug plus chemo for stage 4 colorectal cancer
This study tests a new experimental drug (PF-08634404) combined with standard chemotherapy for people with stage 4 colorectal cancer who have not yet been treated for their advanced disease. The goal is to see if the combination helps shrink or slow the growth of tumors.
Chandler, ArizonaAges 18 years+ - NCT05310643RecruitingPhase 2
Nivolumab and ipilimumab for bowel cancer resistant to anti-PD1
This Phase 2 study tests two immunotherapy medicines (nivolumab and ipilimumab) in people with metastatic colorectal cancer that has not responded to anti-PD1 treatment. It focuses on tumors with mismatch repair problems (dMMR) and/or high microsatellite instability (MSI).
BesançonAges 18 years+ - NCT06853496RecruitingPhase 1
RK-582 for advanced colorectal cancer
This trial tests a new type of pill called RK-582 that may help block the growth of colorectal cancer cells. It is for people whose cancer has spread and hasn't gotten better with other treatments.
Koto-ku, TokyoAges 18 years+ - NCT02885753RecruitingPhase 3
Liver-only metastatic colon cancer trial using targeted chemo
This Phase 3 trial tests different ways to deliver chemotherapy for colon cancer that has spread only to the liver (with limited possible tiny lung spots). It looks at whether the treatment plan improves outcomes compared with another chemotherapy approach, using oxaliplatin and LV5FU2 (with or without irinotecan) plus an added targeted medicine.
BrusselsAges 18 years+ - NCT05787197Recruiting
Blood test to guide treatment after colon cancer liver surgery
This trial studies a blood test (called ctDNA) in people with colon cancer that has spread to the liver and is being removed with curative surgery. The goal is to see how the blood test can help with planning and improving treatment after surgery.
BesançonAges 18 years+
Hear when a new Metastatic Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic lung cancer?
- Yes. Clin2 currently lists 1,188 recruiting metastatic lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Lung Cancer (Locally Advanced or Metastatic)
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Metastatic Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.